Pharmacodynamics and clinical effectiveness of clopidogrel and atorvastin in patients with acute coronary syndrome and hyperlipidaemia
Aim. To study pharmacodynamics and clinical effectiveness of clopidogrel and atorvastatin in patients with acute coronary syndrome (ACS) and hyperlipidaemia (HLP).Material and methods. The study included 90 patients with ACS and Type IIA or IIB HLP. Group I received clopidogrel monotherapy, Group II...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2009-08-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1820 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849250463796428800 |
|---|---|
| author | A. S. Sivkov S. V. Paukov R. Sh. Balugyan V. G. Kukes M. V. Zhuravleva S. I. Sivkov T. N. Farafonova |
| author_facet | A. S. Sivkov S. V. Paukov R. Sh. Balugyan V. G. Kukes M. V. Zhuravleva S. I. Sivkov T. N. Farafonova |
| author_sort | A. S. Sivkov |
| collection | DOAJ |
| description | Aim. To study pharmacodynamics and clinical effectiveness of clopidogrel and atorvastatin in patients with acute coronary syndrome (ACS) and hyperlipidaemia (HLP).Material and methods. The study included 90 patients with ACS and Type IIA or IIB HLP. Group I received clopidogrel monotherapy, Group II — a combination of clopidogrel and atorvastatin, and Group III — atorvastatin monotherapy. Blood lipid profile (LP), induced platelet aggregation (IPLA), and cytochrome P-450 3A4 isoenzyme were measured.Results. Clopidogrel did not affect blood LP, but significantly reduced IPLA. Its effectiveness was also demonstrated in combination with atorvastatin, despite reduced activity of cytochrome P-450 3A4 isoenzyme. Lipidlowering effect of atorvastatin was observed both for monotherapy and its combination with clopidogrel. Atorvastatin monotherapy has a mild anti-aggregant effect: IPLA was reduced as early as during the third month of the treatment.Conclusion. High effectiveness of an anti-platelet agent clopidogrel and a lipid-lowering medication atorvastatin opens a window for their wide use in cardiologic practice, in particular, for ACS patients. |
| format | Article |
| id | doaj-art-4d48f07da28b4572a6d1cd3ddc8de9a5 |
| institution | Kabale University |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 2009-08-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-4d48f07da28b4572a6d1cd3ddc8de9a52025-08-20T03:57:17Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252009-08-018476831535Pharmacodynamics and clinical effectiveness of clopidogrel and atorvastin in patients with acute coronary syndrome and hyperlipidaemiaA. S. Sivkov0S. V. Paukov1R. Sh. Balugyan2V. G. Kukes3M. V. Zhuravleva4S. I. Sivkov5T. N. Farafonova6I.M. Sechenov Moscow Medical Academy“Medsantrud” City Clinical Hospital No. 23“Medsantrud” City Clinical Hospital No. 23I.M. Sechenov Moscow Medical AcademyI.M. Sechenov Moscow Medical AcademyI.M. Sechenov Moscow Medical AcademyI.M. Sechenov Moscow Medical AcademyAim. To study pharmacodynamics and clinical effectiveness of clopidogrel and atorvastatin in patients with acute coronary syndrome (ACS) and hyperlipidaemia (HLP).Material and methods. The study included 90 patients with ACS and Type IIA or IIB HLP. Group I received clopidogrel monotherapy, Group II — a combination of clopidogrel and atorvastatin, and Group III — atorvastatin monotherapy. Blood lipid profile (LP), induced platelet aggregation (IPLA), and cytochrome P-450 3A4 isoenzyme were measured.Results. Clopidogrel did not affect blood LP, but significantly reduced IPLA. Its effectiveness was also demonstrated in combination with atorvastatin, despite reduced activity of cytochrome P-450 3A4 isoenzyme. Lipidlowering effect of atorvastatin was observed both for monotherapy and its combination with clopidogrel. Atorvastatin monotherapy has a mild anti-aggregant effect: IPLA was reduced as early as during the third month of the treatment.Conclusion. High effectiveness of an anti-platelet agent clopidogrel and a lipid-lowering medication atorvastatin opens a window for their wide use in cardiologic practice, in particular, for ACS patients.https://cardiovascular.elpub.ru/jour/article/view/1820acute coronary syndromearterial hypertensionhyperlipidaemiatreatment |
| spellingShingle | A. S. Sivkov S. V. Paukov R. Sh. Balugyan V. G. Kukes M. V. Zhuravleva S. I. Sivkov T. N. Farafonova Pharmacodynamics and clinical effectiveness of clopidogrel and atorvastin in patients with acute coronary syndrome and hyperlipidaemia Кардиоваскулярная терапия и профилактика acute coronary syndrome arterial hypertension hyperlipidaemia treatment |
| title | Pharmacodynamics and clinical effectiveness of clopidogrel and atorvastin in patients with acute coronary syndrome and hyperlipidaemia |
| title_full | Pharmacodynamics and clinical effectiveness of clopidogrel and atorvastin in patients with acute coronary syndrome and hyperlipidaemia |
| title_fullStr | Pharmacodynamics and clinical effectiveness of clopidogrel and atorvastin in patients with acute coronary syndrome and hyperlipidaemia |
| title_full_unstemmed | Pharmacodynamics and clinical effectiveness of clopidogrel and atorvastin in patients with acute coronary syndrome and hyperlipidaemia |
| title_short | Pharmacodynamics and clinical effectiveness of clopidogrel and atorvastin in patients with acute coronary syndrome and hyperlipidaemia |
| title_sort | pharmacodynamics and clinical effectiveness of clopidogrel and atorvastin in patients with acute coronary syndrome and hyperlipidaemia |
| topic | acute coronary syndrome arterial hypertension hyperlipidaemia treatment |
| url | https://cardiovascular.elpub.ru/jour/article/view/1820 |
| work_keys_str_mv | AT assivkov pharmacodynamicsandclinicaleffectivenessofclopidogrelandatorvastininpatientswithacutecoronarysyndromeandhyperlipidaemia AT svpaukov pharmacodynamicsandclinicaleffectivenessofclopidogrelandatorvastininpatientswithacutecoronarysyndromeandhyperlipidaemia AT rshbalugyan pharmacodynamicsandclinicaleffectivenessofclopidogrelandatorvastininpatientswithacutecoronarysyndromeandhyperlipidaemia AT vgkukes pharmacodynamicsandclinicaleffectivenessofclopidogrelandatorvastininpatientswithacutecoronarysyndromeandhyperlipidaemia AT mvzhuravleva pharmacodynamicsandclinicaleffectivenessofclopidogrelandatorvastininpatientswithacutecoronarysyndromeandhyperlipidaemia AT sisivkov pharmacodynamicsandclinicaleffectivenessofclopidogrelandatorvastininpatientswithacutecoronarysyndromeandhyperlipidaemia AT tnfarafonova pharmacodynamicsandclinicaleffectivenessofclopidogrelandatorvastininpatientswithacutecoronarysyndromeandhyperlipidaemia |